^
Association details:
| Biomarker: | BCR-FGFR1 fusion |
|---|---|
| Cancer: | Leukemia |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) + ganetespib (ADX-1612) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 5933: Biochemical characterization of FGFR2-PPHLN1 and BCR-FGFR1, drivers of epithelial and hematological malignancies
Published date:
06/23/2020
Excerpt:
Transformed cells expressing BCR-FGFR1 are sensitive to the Hsp90 inhibitor, Ganetespib, and also respond to combined treatment with Ganetespib and FGFR inhibitor BGJ398, suggesting novel clinical treatment options for patients positive for this fusion.
DOI:
10.1158/1538-7445.AM2020-5933
